Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 801–900 of 1,004
Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease
Lamprea-Montealegre, J. A., McClelland, R. L., Grams, M. E., Ouyang, P., Szklo, M., & de Boer, I. H. (2018) · Heart · doi:10.1136/heartjnl-2017-312794 · Cited by 33
Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
Hwang, H. S., Kim, J. S., Kim, Y., Lee, S., Ahn, S. Y., Lee, H. J., Lee, D.-Y., Lee, S. H., Moon, J.-Y., & Jeong, K. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010244 · Cited by 33
Chronic kidney disease as a cardiovascular risk factor
Carmena, R., Ascaso, J. F., & Redón, J. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002506 · Cited by 39
Jun, M., Lv, J., Perkovic, V., & Jardine, M. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311401775 · Cited by 39
Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment
House, A. A. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.11.006 · Cited by 33
Bro, S., Binder, C. J., Witztum, J. L., Ølgaard, K., & Nielsen, L. B. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.139634 · Cited by 33
Cardiovascular disease in patients with renal disease: the role of statins
Fellström, B., Holdaas, H., Jardine, A. G., Svensson, M. K. E., Gottlow, M., Schmieder, R. E., Zannad, F. M., & on behalf of the AURORA Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802622064 · Cited by 37
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia
Ferreira, A. M., & da Silva, P. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0205-0 · Cited by 35
Holdaas, H., Wanner, C., Abletshauser, C., Gimpelewicz, C. R., & Isaacsohn, J. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.06.003 · Cited by 33
Self-citationIndividualising Therapy for Older Adults with Diabetes Mellitus
Cayea, D., Boyd, C. M., & Durso, S. C. (2007) · Drugs & Aging · doi:10.2165/00002512-200724100-00005 · Cited by 35
Indoxyl Sulfate-Induced Macrophage Toxicity and Therapeutic Strategies in Uremic Atherosclerosis
Wakamatsu, T., Yamamoto, S., Yoshida, S., & Narita, I. (2024) · Toxins · doi:10.3390/toxins16060254 · Cited by 32
Son, B., Akishita, M., Iijima, K., Eto, M., & Ouchi, Y. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e545 · Cited by 32
Statins in chronic kidney disease and kidney transplantation
Kassimatis, T. I., & Goldsmith, D. J. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.011 · Cited by 35
Agrawal, H., Aggarwal, K. B., Littrell, R. L., Velagapudi, P., Turagam, M. K., Mittal, M., & Alpert, M. (2015) · Current Cardiology Reviews · doi:10.2174/1573403x1103150514155757 · Cited by 35
Ulrich, C., Seibert, E., Heine, G. H., Fliser, D., & Girndt, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06870810 · Cited by 32
Effects of Rosuvastatin and Atorvastatin on Renal Function
Wu, Y., Wang, Y., An, C., Dong, Z., Liu, H., Zhang, Y., Zhang, M., & An, F. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1385 · Cited by 32
Protein Carbamylation in Chronic Kidney Disease and Dialysis
Long, J., Parada, X. F. V., & Kalim, S. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.07.002 · Cited by 32
March, D. S., Jones, A. W., BISHOP, N. C., & Burton, J. O. (2019) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2019.07.006 · Cited by 38
Li, X., Huang, S., Chen, X., Xu, Q., Ma, Y., You, L., Kulikouskaya, V. I., Xiao, J., & Piao, J. (2020) · Food & Function · doi:10.1039/d0fo02575e · Cited by 32
The cardiovascular–dialysis nexus: the transition to dialysis is a treacherous time for the heart
Chan, K. T. K., Moe, S. M., Saran, R., & Libby, P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1049 · Cited by 32
Dyslipidemia in Patients with Kidney Disease
Thobani, A., & Jacobson, T. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.008 · Cited by 36
Clinical assessment and management of dyslipidemia in patients with chronic kidney disease
Nitta, K. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0655-x · Cited by 35
Dyslipidemia in Dialysis Patients
Qunibi, W. Y. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12375 · Cited by 34
DiNicolantonio, J. J., Lavie, C. J., Serebruany, V. L., & O’Keefe, J. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2620 · Cited by 34
Fahim, M., Hayen, A. D., Horvath, A. R., Dimeski, G., Coburn, A., Tan, K., Johnson, D. W., Craig, J. C., Campbell, S. B., & Hawley, C. M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0838 · Cited by 32
Ivanovski, O., Szumilak, D., Nguyen‐Khoa, T., Nikolov, I. G., Joki, N., Mothu, N., Maizel, J., Westenfeld, R., Ketteler, M., Lacour, B., et al. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.11.042 · Cited by 32
Modulation of stroke risk in chronic kidney disease
Arnold, J. J., Sims, D., & Ferro, C. J. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv136 · Cited by 34
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 37
Elevated TG/HDL-C and non-HDL-C/HDL-C ratios predict mortality in peritoneal dialysis patients
Xia, W., Yao, X., Chen, Y., Lin, J., Vielhauer, V., & Hu, H. W. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01993-5 · Cited by 32
Glynn, L. G., Reddan, D. N., Newell, J., Hinde, J., Buckley, B. S., & Murphy, A. W. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm222 · Cited by 39
Delles, C., & Vanholder, R. C. (2017) · Clinical Science · doi:10.1042/cs20160624 · Cited by 32
Franczyk, B., Gluba-Brzózka, A., Banach, M., & Rysz, J. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.39792 · Cited by 33
MACGREGOR, M. S., & Taal, M. W. (2011) · Nephron Clinical Practice · doi:10.1159/000328062 · Cited by 34
Medical options to fight mortality in end-stage renal disease: a review of the literature
Kramann, R., Floege, J., Ketteler, M., Marx, N., & Brandenburg, V. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs400 · Cited by 35
Drechsler, C., Hayek, S. S., Wei, C., Sever, S., Genser, B., Krane, V., Meinitzer, A., März, W., Wanner, C., & Reiser, J. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10881016 · Cited by 31
Self-citationChiang, C., Yang, S., Peng, Y., Hsu, S.-P., Pai, M., Huang, J.-W., Hung, K., & Wu, K. (2008) · American Journal of Nephrology · doi:10.1159/000169658 · Cited by 31
Chan, C. T., Covic, A. C., Craig, J. C., Davenport, A., Kasiske, B. L., Kuhlmann, M. K., Levin, N. W., Li, P. K., Locatelli, F., Rocco, M. V., et al. (2013) · Kidney International · doi:10.1038/ki.2012.450 · Cited by 34
Dyslipidemia in renal disease: Causes, consequences and treatment
Mesquita, J., Varela, A. T. I. F., & Medina, J. L. (2010) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.06.003 · Cited by 37
McCullough, P. A., & Verrill, T. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2119 · Cited by 38
Kalil, R. S., Flanigan, M. J., Stanford, W. P., & Haynes, W. G. (2011) · Clinical Nephrology · doi:10.5414/cn106830 · Cited by 32
Jurkovitz, C. T., Elliott, D. J., Li, S., Saab, G., Bomback, A. S., Norris, K. C., Chen, S., McCullough, P. A., & Whaley‐Connell, A. T. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.11.019 · Cited by 31
Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk
Pun, P. H., & Middleton, J. P. (2012) · Blood Purification · doi:10.1159/000334154 · Cited by 33
Impact of vitamin A on clinical outcomes in haemodialysis patients
Espe, K. M., Raila, J., Henze, A., Krane, V., Schweigert�, F. J., Hocher, B., Wanner, C., Drechsler, C., & for the German Diabetes and Dialysis Study Investigators (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr171 · Cited by 32
Self-citationChung, C., Lin, M., Chang, C., Cheng, H.-W., Chang, S., Wang, P., Chang, H., & Lin, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.018 · Cited by 31
Cardiovascular Mortality in the General Population Versus Dialysis: A Glass Half Full or Empty?
Sarnak, M. J., & Foley, R. N. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.04.004 · Cited by 32
Bybee, K. A., Lee, J., & O’Keefe, J. H. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292001 · Cited by 33
Sunset for Statins after AURORA?
Strippoli, G. F., & Craig, J. C. (2009) · New England Journal of Medicine · doi:10.1056/nejme0901067 · Cited by 31
Latest US KDOQI Anaemia Guidelines update what are the implications for Europe?
Macdougall, I. C., Eckardt, K., & Locatelli, F. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm562 · Cited by 31
Wang, L., Tian, W., Zaid, U. B., Li, G., Li, H., Guan, R., Gao, Z., & Xin, Z. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12533 · Cited by 30
Effects of statin treatment in patients with coronary artery disease and chronic kidney disease
Kaneko, H., Yajima, J., Oikawa, Y., Tanaka, S., Fukamachi, D., Suzuki, S. S., Sagara, K., Otsuka, T., Matsuno, S., Funada, R., et al. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0325-2 · Cited by 30
Bertoluci, M. C., Netto, A. P., Pires, A. C., Pesaro, A. E. P., Schaan, B. D., Caramelli, B., Polanczyk, C. A., Junior, C. V. S., Gualandro, D. M., Malerbi, D. A. C., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-58 · Cited by 34
The assessment of coronary artery disease in patients with end-stage renal disease
Poli, F. E., Gulsin, G. S., McCann, G. P., Burton, J. O., & Graham-Brown, M. P. M. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz088 · Cited by 36
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 30
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
Mathew, R. O., Rosenson, R. S., Lyubarova, R., Chaudhry, R., Costa, S. P., Bangalore, S., & Sidhu, M. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07020-x · Cited by 32
Zhou, C., He, Q., Gan, H., Zeng, T., Liu, Q., Moorhead, J. F., Varghese, Z., Ouyang, N., & Ruan, X. Z. (2021) · Kidney International · doi:10.1016/j.kint.2021.01.016 · Cited by 30
Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease
Omran, J., Al‐Dadah, A., & Dellsperger, K. C. (2013) · Cardiorenal Medicine · doi:10.1159/000351985 · Cited by 30
Is Lipid Control Necessary in Hemodialysis Patients?
Cheung, A. K. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04780709 · Cited by 30
Wald, R., Yan, A. T.-K., Perl, J. M., Jiang, D., Donnelly, M. S., Leong-Poi, H. M., McFarlane, P. A., Weinstein, J. J., & Goldstein, M. B. (2012) · BMC Nephrology · doi:10.1186/1471-2369-13-3 · Cited by 30
Effects of Dialysis Purity on Uremic Dyslipidemia
Schiffl, H. H., & Lang, S. M. (2009) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2009.00713.x · Cited by 30
Weisbord, S. D., Shields, A. M., Mor, M. K., Sevick, M. A., Homer, M., Peternel, J., Porter, P., Rollman, B. L., Palevsky, P. M., Arnold, R. M., et al. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.06.005 · Cited by 30
Łuczak, M., Formanowicz, D., Marczak, Ł., Pawliczak, E., Wanic-Kossowska, M., Figlerowicz, M., & Stobiecki, M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0378-8 · Cited by 33
Apoprotein B/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients
Sato, Y., Fujimoto, S., Toida, T., Nakagawa, H., Yamashita, Y., Iwakiri, T., Fukuda, A., & Iwatsubo, S. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09830915 · Cited by 30
Pateinakis, P., & Papagianni, A. A. (2011) · International Journal of Nephrology · doi:10.4061/2011/938651 · Cited by 36
Cleland, J. G. F., Coletta, A. P., Clark, A. L., & Cullington, D. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp071 · Cited by 32
HMG CoA reductase inhibitors (statins) for dialysis patients
Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004289.pub4 · Cited by 30
Nowak, K. L., & Chonchol, M. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.06.019 · Cited by 30
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Statins in patients with chronic kidney disease: why, who and when?
Gluba-Brzózka, A., Rysz, J., & Banach, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.512419 · Cited by 30
The effect of decreasing renal function on lipoprotein profiles
Attman, P.-O., Samuelsson, O. G., & Alaupovic, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq762 · Cited by 31
Extra-skeletal effects of vitamin D deficiency in chronic kidney disease
Chonchol, M., Kendrick, J., & Targher, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.543923 · Cited by 31
Suguro, R., Chen, S., Yang, D., Yang, Z., Miao, L., Wu, W., Zeng, W., Liu, X., & Zhu, Y. Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01468 · Cited by 31
Ma, W., Pan, Q., Pan, D., Xu, T., Zhu, H., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713007 · Cited by 31
Barayev, O., Hawley, C. E., Wellman, H., Gerlovin, H., Hsu, W., Paik, J. M., Mandel, E. I., Liu, C., Djoussé, L., Gaziano, J. M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.46373 · Cited by 30
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
Vascular disease and chronic renal failure: new insights.
Nanayakkara, P. W. B., & Gaillard, S. (2010) · PubMed · Cited by 33
Randomized Controlled Trials in Nephrology: State of the Evidence and Critiquing the Evidence
Samuels, J., & Molony, D. A. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.01.009 · Cited by 31
Clinical evidence of statin therapy in non-dyslipidemic disorders
Ferri, N., & Corsini, A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.003 · Cited by 31
Serum β-Trace Protein and Risk of Mortality in Incident Hemodialysis Patients
Shafi, T., Parekh, R. S., Jaar, B. G., Plantinga, L., Oberai, P. C., Eckfeldt, J. H., Levey, A. S., Powe, N. R., & Coresh, J. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02240312 · Cited by 29
Chen, N., Wu, X., Ding, X., Mei, C., Fu, P., Jiang, G., Li, X., Chen, J., Liu, B., La, Y., et al. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft232 · Cited by 29
MicroRNA-142-3p improves vascular relaxation in uremia
Kétszeri, M., Kirsch, A., Frauscher, B., Moschovaki-Filippidou, F., Mooslechner, A. A., Kirsch, A. H., Schabhüttl, C., Aringer, I., Artinger, K., Pregartner, G., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.024 · Cited by 29
(2007) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21475 · Cited by 29
Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis
Adler, S. G. (2006) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70449-8 · Cited by 29
Vaziri, N. D., & Norris, K. C. (2013) · Blood Purification · doi:10.1159/000345176 · Cited by 33
Kajinami, K., & Yasusyuki, K. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s13492 · Cited by 31
Choe, A. R., Ryu, D., Kim, H. Y., Lee, H. A., Lim, J.-Y., Kim, J. S., Lee, J. K., Kim, T. H., & Yoo, K. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01718-8 · Cited by 31
Haroon, S. W. P., Tai, B., Ling, L. H., Teo, L., Davenport, A., Schurgers, L. J., Teo, B. W., Khatri, P., Ong, C. C., Low, S., et al. (2020) · Medicine · doi:10.1097/md.0000000000021906 · Cited by 28
Kosugi, T., Eriguchi, M., Yoshida, H., Tasaki, H., Fukata, F., Nishimoto, M., Matsui, M., Samejima, K., Iseki, K., Fujimoto, S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.004 · Cited by 29
Noh, H.-W., Jeon, Y., Kim, J., Lee, G. Y., Jeon, S., Kim, K.-Y., Lim, J., Jung, H., Choi, J., Park, S.-H., et al. (2021) · Nutrients · doi:10.3390/nu14010144 · Cited by 31
Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort
Pinter, J., Smyth, B. J., Stuard, S., Jardine, M., Wanner, C., Rossignol, P., Wheeler, D. C., Marshall, M. R., Canaud, B., & Genser, B. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000262 · Cited by 28
Self-citationKollerits, B., Krane, V., Drechsler, C., Lamina, C., März, W., Ritz, E., Wanner, C., Kronenberg, F., & The German Diabetes and Dialysis Study Investigators (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02585.x · Cited by 30
Self-citationGhanta, M., Kozicky, M., & Jim, B. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000044 · Cited by 32
Clinical Practice Guidelines in nephrology—for worse or for better
Uhlig, K., Balk, E. M., Lau, J., & Levey, A. S. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl084 · Cited by 29
Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada
Kitchlu, A., Clemens, K. K., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Manno, M., Oliver, M. J., Quinn, R. R., Suri, R. S., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr460 · Cited by 33
Management of the Diabetic Patient with Advanced Chronic Kidney Disease
Alicic, R. Z., & Tuttle, K. R. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00700.x · Cited by 28
Nephrology research—the past, present and future
Floege, J., MAK, R. H. K., Molitoris, B. A., Remuzzi, G., & Ronco, P. M. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.152 · Cited by 29
Ventricular arrhythmia in chronic kidney disease patients
Bonato, F. O. B., & Canziani, M. E. F. (2017) · Brazilian Journal of Nephrology · doi:10.5935/0101-2800.20170033 · Cited by 33
Poulikakos, D. J., Hnatkova, K., Skampardoni, S., Green, D., Kalra, P. A., & Malík, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00144 · Cited by 28
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1649394 · Cited by 28
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Baigent, C., Landray, M., & Wheeler, D. C. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00340.x · Cited by 28
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.